🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

$nrsn Breaking News! We are pleased to share that the pre-defined Per Protocol analysis of the top-line Phase 2b PARADIGM trial results revealed a statistically significant 37.4% difference in ALSFRS-R in patients treated with PrimeC vs. placebo, demonstrating PrimeC’s potential

$nrsn I'm humbly honored by the ALS community and industry, who are excited by our remarkable Phase 2b ALS study results and have been sending their congratulations. I thank all of our collaborators and the devoted team for genuinely caring for the patients and for this

Sounding Board Opportunity: I am seeking creative and experienced individuals from various disciplines to form a sounding board. The role involves providing feedback on various aspects of our projects. Initially, this will be a volunteer role with the potential for compensation

$nrsn I'm excited to share these news. Across the board we see positive impact on patient's lives. Soon enough we'll be updating on the NfLs which are an important biomarker that reflects disease progression. NfLs are valued highly by the FDA and of course - by us too.

I'm honored to be the keynote speaker at the "Rare Disease Biotech Summit," where I'll share our remarkable journey at NeuroSense Therapeutics in "Transforming ALS Treatment from Idea to Reality." This experience has been a testament to the power of innovation, collaboration, and

The ALS community is facing a tough day, grappling with the news that Amylyx's Phase 3 study did not meet its primary or secondary endpoints. It's a moment of collective disappointment, yet it's also a moment that reminds us of the power of resilience and hope. My friend Shay

I am pleased to share news about our synergistic collaboration with $LONN $NRSN $LONN.SW lonza.com/media-advisori…

Happy to share that NeuroSense Therapeutics has been granted the prestigious AAN Late Breaker slot. A heartfelt thank you to Prof. Merit Cudkowicz for presenting the outcomes of our Paradigm study! $NRSN finance.yahoo.com/news/neurosens…

$NRSN Quarterly updates New Data from the PARADIGM trial to be shared soon. Stay Tuned prnewswire.com/news-releases/…

This is outstanding $NRSN prnewswire.com/news-releases/…

Today, we honor the legacy of Lou Gehrig, the legendary New York Yankees player who passed away on this day in 1941 due to #ALS. Gehrig not only made a lasting mark on baseball, but he also brought national attention to Amyotrophic Lateral Sclerosis. His courage and resilience

$NRSN Distinguished 12-month results from the PARADIGM ALS clinical trial finance.yahoo.com/news/neurosens…

$NRSN I thank Prof. Jeremy Shefner for his continued support. He states, "The latest results from the PARADIGM study are incredibly encouraging and provide compelling evidence of PrimeC's potential to significantly benefit people living with ALS. The substantial improvement in

We look forward to continued communications on developments, as appropriate, including biomarker readouts for target engagement, which we expect will shed additional light on PrimeC's potential to benefit people who suffer from ALS. $NRSN

As previously reported, NeuroSense looks forward to reporting biomarker readouts for target engagement this month! 🙂

$NRSN We look forward to reporting biomarker readouts for target engagement soon.

Exciting progress in the fight against ALS! 🎉 $NRSN 12-month PARADIGM study data shows promising regulation of iron levels, correlating with significant improvements in ALS survival and disease mitigation. Positive biomarker data alongside clinical efficacy brings us one step

ICYMI. I wanted to share the press release from NeuroSense Therapeutics so that you can see for yourselves the data and make your own assessment of it. prnewswire.com/news-releases/…

Recent times have taught us that messaging is everything. Soon, we’ll be sharing news through the right channels, ensuring it’s clear and far-reaching. With the best results ever in a 12-month ALS trial, I’m personally committed to delivering on our promise efficiently. $NRSN

🎉 Exciting news for all our NeuroSense Therapeutics stakeholders! Stay connected and get the latest updates faster than ever. Join our channel now to stay in the loop: $NRSN whatsapp.com/channel/0029Va…